By current IMWG consensus guidelines, one of the criteria for measurable disease in MM is defined as an involved free light chain (iFLC) greater than 100 mg/L.3 In this study, we identified more MM patients with measurable disease by the Freelite assay (61.97%) than with the N Latex FLC assay (52.11%). This evidence concerns the gene TNFSF14 and Miyoshi myopathy.